Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1/2
    1
    25%
    Not Applicable
    2
    50%
    Phase 1
    1
    25%

    Phase Distribution

    1

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    1(25.0%)
    Phase 1/2Combined phases
    1(25.0%)
    N/ANon-phased studies
    2(50.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Active(1)
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Withdrawn1
    Not yet recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 11 (25.0%)
    Phase 1/21 (25.0%)
    N/A2 (50.0%)

    Trials by Status

    withdrawn125%
    not_yet_recruiting125%
    completed250%

    Recent Activity

    0 active trials
    Showing 4 of 4
    withdrawnphase_1_2

    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

    NCT05909527
    not_yet_recruitingnot_applicable

    CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

    NCT07008872
    completednot_applicable

    Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

    NCT04938115
    completedphase_1

    Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

    NCT04572308

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT05909527Phase 1/2

    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

    Withdrawn
    NCT07008872Not Applicable

    CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

    Not Yet Recruiting
    NCT04938115Not Applicable

    Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

    Completed
    NCT04572308Phase 1

    Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    4